Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Cutaneous aspergillosis as a first manifestation of systemic infection in allogeneic haematopoietic stem cell transplantation.

Authors:
Khalil Ullah Hashmi Parvez Ahmed Tariq Mahmood Satti Shahid Raza Qama-un-Nissa Chaudhry Aamer Ikram Muhammad Khalid Kamal Farrukh Mahmood Akhtar

J Pak Med Assoc 2007 Jun;57(6):324-6

Departments of Haematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi.

Infections are one of the major causes of morbidity and mortality after stem cell transplantation (SCT). Opportunistic infections of varying severity with bacterial fungal and viral organisms occur in > 90% of patients after allogeneic SCT. Fatal opportunistic infections have been reported in 4-15% of related transplant recipients and 12-28% of unrelated transplant recipients. More than half of the transplant patients affected by invasive aspergillosis die despite treatment. Cutaneous aspergillosis has been rarely reported in transplant patients. During last five years 154 patients underwent allo SCT at our centre for various haematological disorders. Aspergillus infection was observed in six patients. Three patients had systemic aspergillosis whereas other three patients had primary cutaneous aspergillus infection. Patients with primary cutaneous aspergillosis are presented here as case report.

Download full-text PDF

Source
June 2007

Publication Analysis

Top Keywords

cutaneous aspergillosis
12
patients
8
opportunistic infections
8
cell transplantation
8
transplant patients
8
three patients
8
primary cutaneous
8
patients primary
8
stem cell
8
aspergillus infection
8
transplant recipients
8
allogeneic haematopoietic
4
unrelated transplant
4
12-28% unrelated
4
recipients half
4
half transplant
4
invasive aspergillosis
4
aspergillosis
4
patients invasive
4
patients three
4

Similar Publications

[Mycobacterium abscessus and Mycobacterium tuberculosis coinfection in a patient with exogenous Cushing syndrome and other comorbilities].

Authors:
Gino Patrón-Ordóñez Félix Llanos-Tejada Dayanne Benites-Gamboa César Espinoza-Chiong

Rev Peru Med Exp Salud Publica 2020 Oct-Dec;37(4):762-766. Epub 2021 Feb 3.

Facultad de Medicina Humana, Universidad Ricardo Palma, Lima, Perú.

Mycobacterium abscessus is a fast-growing non-tuberculous mycobacterium that causes lung, skin, disseminated and other infections, mainly in patients with comorbidities. The diagnosis is based on the identification of the mycobacterium by culture media or molecular tests. Treatment with macrolides and amikacin remains the optimal choice, although it depends on the location and severity of the infection; however, resistance genes have been identified in some subspecies that limit antibiotic efficacy. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Estimates of serious fungal infection burden in Côte d'Ivoire and country health profile.

Authors:
D Koffi I V Bonouman A O Toure F Kouadjo M R E N'Gou K Sylla M Dosso D W Denning

J Mycol Med 2020 Nov 21;31(1):101086. Epub 2020 Nov 21.

Manchester Fungal Infection Group, faculty of medicine, biology and health, university of Manchester and Manchester academic health science centre, Manchester, UK.

Due to limited access to more powerful diagnostic tools, there are few data on the burden of fungal infections in Côte d'Ivoire, despite a high HIV and TB burden and many cutaneous diseases. Here we estimate the burden of serious fungal infections in this sub-Saharan country with a health profiling description. National demographics were used and PubMed searches to retrieve all published articles on fungal infections in Côte d'Ivoire and other bordering countries in West Africa. Read More

View Article and Full-Text PDF
November 2020
Similar Publications

Primary Cutaneous Aspergillosis in a Patient with CARD9 Deficiency and Aspergillus Susceptibility of Card9 Knockout Mice.

Authors:
Yi Zhang Chen Huang Yinggai Song Yubo Ma Zhe Wan Xuejun Zhu Xiaowen Wang Ruoyu Li

J Clin Immunol 2021 Feb 12;41(2):427-440. Epub 2020 Nov 12.

Department of Dermatology and Venerology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.

Purpose: We describe a case of primary cutaneous aspergillosis caused by Aspergillus fumigatus, and elucidate the underlying genetic and immunological mechanisms.

Materials And Methods: Routine clinical and laboratory investigations were performed. Whole-exome sequencing of the patient's DNA suggested the presence of a CARD9 mutation, which was confirmed by Sanger sequencing. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital.

Authors:
Joanne Abbotsford David A Foley Zoy Goff Asha C Bowen Christopher C Blyth Daniel K Yeoh

J Antimicrob Chemother 2021 Jan;76(1):249-252

Department of Infectious Diseases, Perth Children's Hospital, Nedlands, Western Australia, Australia.

Background: Itraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.

Objectives: To assess the safety, efficacy and attainment of therapeutic drug levels of the SUBA-itraconazole formulation in children. Read More

View Article and Full-Text PDF
January 2021
Similar Publications

The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis.

Authors:
Chris Kosmidis Anna Mackenzie Chris Harris Rola Hashad Fiona Lynch David W Denning

Naunyn Schmiedebergs Arch Pharmacol 2020 11 21;393(11):2233-2237. Epub 2020 Aug 21.

Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

Voriconazole has been associated with cutaneous squamous cell carcinoma (cSCC) in transplant patients but less is known about the risk in less severely immunosuppressed patients. Our aim was to estimate the incidence of cSCC after voriconazole exposure in patients with chronic pulmonary aspergillosis on a background of chronic lung disease. The notes of patients seen at a tertiary referral centre from 2009 to 2019 with chronic pulmonary aspergillosis were reviewed for the diagnosis of cSCC and voriconazole use documented. Read More

View Article and Full-Text PDF
November 2020
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap